NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
Recruiting · NCT05661201 · Registry updated 2026-03-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors | KRAS Mutation-Related Tumors; Solid Tumor | Recruiting | Phase 1 | 2026-03-06 | NCT05661201 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Georgetown University | 73 |
| Immune System Key Ltd | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Georgetown Lombardi Comprehensive Cancer Center | Washington D.C. | United States | 14 |